文献速递母胎医学

一种可用于遗传性听力损失无创产前诊断的胎儿基因分型检测方法的开发与验证

Development and validation of a fetal genotyping assay with potential for noninvasive prenatal diagnosis of hereditary hearing loss.
PubMed 文献 · Prenat Diagn · 2016-12-09

该研究采用cSMART技术对孕妇血浆游离DNA进行非综合征性遗传性听力损失(NSHL)无创产前检测。回顾性分析25份不同胎儿NSHL基因型血浆样本,cSMART检出的全部25例胎儿基因型与新生儿SNaPshot基因分型结果一致。

要点

  • cSMART技术可对GJB2、GJB3和SLC26A4基因的胎儿NSHL突变进行无创产前检测。
  • 25份血浆样本中检出3例正常胎儿、18例携带者胎儿和4例患病胎儿。
  • 25例胎儿基因型均与新生儿基因型一致。

核心结论

  • 应用于孕妇血浆游离DNA的cSMART检测在判定胎儿NSHL基因型方面高度准确。

研究设计与样本

  • 本研究通过SNaPshot基因分型从血斑确定新生儿NSHL突变的遗传情况,并用多重cSMART检测对孕妇血浆游离DNA中GJB2、GJB3和SLC26A4基因的胎儿NSHL突变进行无创产前检测。
  • 研究选取25份具有不同胎儿NSHL基因型的血浆样本,编码后经无创产前检测回顾性分析。

主要发现

  • 共识别出3例正常胎儿、18例携带者胎儿和4例患病胎儿。
  • 18例携带者胎儿包括7例GJB2 109G>A、4例GBJ2 235delC、3例GJB2 299-300delAT和4例SLC26A4 IVS7-2A>G杂合子。
  • 4例患病胎儿包括2例GJB2 109G>A纯合子、1例GBJ2 235delC纯合子和1例GJB2 235delC/299-300delAT复合杂合子。
  • cSMART检测确定的全部25例胎儿基因型均与新生儿基因型一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Inherited non-syndromic hearing loss (NSHL) is a common sensory disorder that afflicts otherwise healthy individuals. The aim of the study was to evaluate the performance of circulating single molecule amplification and re-sequencing technology (cSMART) for non-invasive prenatal testing (NIPT) of NSHL. METHOD: Neonatal inheritance of NSHL mutations was determined from bloodspots using SNaPshot genotyping. NIPT of cell-free DNA for fetal NSHL mutations in the GJB2, GJB3 and SLC26A4 genes was performed by a multiplex cSMART assay. The percentage of mutant alleles was used to deduce fetal DNA fractions and assign fetal genotypes. RESULTS: A total of 25 plasma samples selected with different fetal NSHL genotypes were coded and retrospectively analyzed by NIPT. Three normal fetuses, 18 carrier fetuses comprising seven GJB2 109G>A, four GBJ2 235delC, three GJB2 299-300delAT and four SLC26A4 IVS7-2A>G heterozygotes and four affected fetuses comprising two GJB2 109G>A homozygotes, one GBJ2 235delC homozygote and one compound GJB2 235delC/299-300delAT heterozygote were identified. All 25 fetal genotypes determined by the cSMART assay were concordant with neonatal genotypes. CONCLUSION: The cSMART assay applied to cell-free DNA isolated from maternal plasma of pregnant women is highly accurate for calling correct fetal NSHL genotypes. © 2016 John Wiley & Sons, Ltd.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Chen Y, Liu Y, Wang B, et al. Development and validation of a fetal genotyping assay with potential for noninvasive prenatal diagnosis of hereditary hearing loss. Prenat Diagn. 2016. PMID: 27862068. doi:10.1002/pd.4962

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。